Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
05:55pm, Tuesday, 12'th Jan 2021
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional sup
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination wit
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
01:03am, Monday, 11'th Jan 2021
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image an
Basel, 11 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) for the treatment of uncomplicated influenza
3 Biotech Technological Developments to Watch Out For in 2021
09:47am, Thursday, 07'th Jan 2021
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Roche's (RHHBY) Immunotherapy Gets Breakthrough Therapy Status
12:02pm, Tuesday, 05'th Jan 2021
Roche's (RHHBY) tiragolumab in combination with Tecentriq wins Breakthrough Therapy designation for the first-line treatment of patients with metastatic non-small cell lung cancer.
Basel, 5 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (
Wide-Moat Stocks On Sale - The January 2021 Heat Map
05:21am, Friday, 01'st Jan 2021
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
Seagen Earns Top Honors from Key Biotech Publication
10:25am, Thursday, 31'st Dec 2020
Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% ye
Shares of Startup Biotechs Soar on Cancer Study Results
06:00pm, Monday, 28'th Dec 2020
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching fo
Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer
11:18am, Wednesday, 23'rd Dec 2020
Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (t
Roche Is A Suitable Addition To Diversified Dividend Growth Portfolios
02:32pm, Tuesday, 22'nd Dec 2020
I was looking at the healthcare sector for ideas lately. After I analyzed Abbott and Owens & Minor, I decided to go international.
Roche's (RHHBY) DME Drug Meets Primary Endpoint in Studies
11:17am, Tuesday, 22'nd Dec 2020
Roche's (RHHBY) investigational bispecific antibody, faricimab, meets the primary endpoints in two late-stage studies for diabetic acular edema.
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investi
